Free Trial

Oragenics (NYSE:OGEN) Trading Down 4.6% - Time to Sell?

Oragenics logo with Medical background

Oragenics, Inc. (NYSE:OGEN - Get Free Report)'s share price traded down 4.6% during mid-day trading on Thursday . The company traded as low as $3.34 and last traded at $3.53. 209,517 shares changed hands during mid-day trading, an increase of 105% from the average session volume of 102,268 shares. The stock had previously closed at $3.70.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen started coverage on shares of Oragenics in a research report on Thursday, May 15th. They set a "sell" rating on the stock.

View Our Latest Stock Report on OGEN

Oragenics Stock Down 4.6%

The stock has a market cap of $75.81 million, a PE ratio of -0.50 and a beta of 0.94. The stock's fifty day moving average price is $5.43 and its 200 day moving average price is $7.89.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oragenics Right Now?

Before you consider Oragenics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oragenics wasn't on the list.

While Oragenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines